High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors-Reference-Cited by-同舟云学术

High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors

Published:2016-10-20 Issue:16 Volume:128 Page:2055-2067
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Batsuli Glaivy¹²,Deng Wei¹,Healey John F.¹,Parker Ernest T.¹^ORCID,Baldwin W. Hunter¹,Cox Courtney¹,Nguyen Brenda¹,Kahle Joerg³,Königs Christoph³,Li Renhao¹^ORCID,Lollar Pete¹^ORCID,Meeks Shannon L.¹²^ORCID

Affiliation:

1. Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA;

2. Children’s Healthcare of Atlanta, Atlanta, GA; and

3. Clinical and Molecular Haemostasis and Immunodeficiency, Department of Paediatrics, Goethe University Hospital, Frankfurt am Main, Germany.

Abstract

Key Points C1 domain antibodies with low inhibitor titers by the Bethesda assay are pathogenic in mice due to increased fVIII clearance. Monoclonal and patient-derived polyclonal anti-fVIII C1 domain antibodies recognize similar B-cell epitopes.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/16/2055/1396748/2055.pdf

Reference46 articles.

1. Inhibitors: resolving diagnostic and therapeutic dilemmas.;Dimichele;Haemophilia,2002

2. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.;Eckhardt;Blood,2013

3. Impact of inhibitors on hemophilia A mortality in the United States.;Walsh;Am J Hematol,2015

4. Hemophilia A in the third millennium.;Franchini;Blood Rev,2013

5. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment.;Earnshaw;Haemophilia,2015

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of perioperative bleeding in acquired hemophilia a secondary to melanoma: Case report;JCA Advances;2024-12

2. Structural basis for inhibition of coagulation factor VIII reveals a shared antigenic hotspot on the C1 domain;Journal of Thrombosis and Haemostasis;2024-09

3. Pathogenic but sweet: factor VIII inhibitor hits the hot spot;Journal of Thrombosis and Haemostasis;2024-09

4. Predicting inhibitor development using a random peptide phage-display library approach in the SIPPET cohort;Blood Advances;2024-06-03

5. Mice possess a more limited natural antihuman factor VIII antibody repertoire than humans that is produced disproportionately by marginal zone B cells;Journal of Thrombosis and Haemostasis;2024-01